HIMS
Hims & Hers Health, Inc.36.86
+0.61+1.68%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q1 '26)
No earnings call transcript available yet
Last Quarter (Q4 '25)
FY Q4 '25
Reaffirms GLP-1 diversification, Labs traction
Q&A reinforces that GLP-1s represent a small minority of subscribers and majority revenue stems from non-weight loss offerings, downplaying regulatory risks amid analyst scrutiny. Labs showed strong pull-through with 70% of users eligible for platform treatments; testosterone and menopause signal $100M run rates soon. International ambitions clarified: unify Hims & Hers brands across 10 key markets in 1-2 years toward $1B+ revenue. Guidance range reflects stage-gated investments in new specialties, tech, and abroad. Diversification trumps GLP-1 fears. Management exudes confidence; watch Labs and hormones ramp for flywheel proof.
Key Stats
Market Cap
8.39BP/E (TTM)
69.55Basic EPS (TTM)
0.53Dividend Yield
0%Recent Filings
8-K
Novo Nordisk GLP-1 partnership
Hims & Hers announced a strategic shift in its U.S. weight loss business on March 9, 2026, partnering with Novo Nordisk to prioritize FDA-approved GLP-1s like Ozempic and Wegovy, arriving later this month. It will cease advertising compounded versions, limiting them to clinically necessary cases, while aligning U.S. and global models. Novo Nordisk dismissed its lawsuit without prejudice. Customer transitions hinge on provider decisions.
10-K
FY2025 results
Hims & Hers Health crushed FY2025 with revenue rocketing 59% y/y to $2.35B, fueled by U.S. sales jumping 53% to $2.21B as subscribers hit 2.51M—up 13%—and monthly revenue per average subscriber soaring 28% to $83, thanks to personalized treatments now over 70% of U.S. revenue. Q4 accelerated the momentum, powering net income to $128M and Adjusted EBITDA to $318M at 14% margins, while Free Cash Flow stayed robust at $57M despite heavy capex on facilities. Buybacks tapped $115M under new programs; liquidity swelled to $929M cash/investments plus $168M revolver room. Regulatory heat on compounded GLP-1s looms large, though.
8-K
59% revenue growth, $318M EBITDA
Hims & Hers crushed 2025 with revenue surging 59% to $2.35B on 2.5M subscribers, up 13%, and Adjusted EBITDA doubling to $318M despite gross margin dipping to 74%. Q4 revenue hit $618M, yet free cash flow flipped negative on heavy capex. Guides 2026 revenue to $2.7B-$2.9B, excluding pending Eucalyptus buy.
8-K
Acquires Eucalyptus for up to $1.15B
Hims & Hers signed a deal on February 19, 2026, to acquire Eucalyptus, an Australia-based digital health firm operating in Australia, UK, Germany, Canada, and Japan, for up to $1.15B enterprise value—$240M upfront cash at mid-2026 close, $710M deferred over 18 months, $200M earnouts through 2028. Up to 60% of deferred/earnout can settle in Hims stock. Deal accelerates global expansion but hinges on regulatory nods.
8-K
New $250M buyback authorized
Hims & Hers Health authorized a $250 million share repurchase program on November 13, 2025, set to expire November 11, 2028, allowing flexible buybacks amid market conditions. This follows the full exhaustion of its prior $100 million program, with 1,334,572 shares repurchased for $55.5 million from October 1 through November 7, 2025. Repurchases signal confidence in valuation. The program remains discretionary and suspendable.
IPO
Website
Employees
Sector
Industry
CURLF
Curaleaf Holdings, Inc.
4.53+0.85
DOCS
Doximity, Inc.
43.80-0.85
HYEX
HEALTHY EXTRACTS INC.
1.99-0.22
IMCC
IM Cannabis Corp.
1.73+0.21
LFMD
LifeMD, Inc.
3.42+0.15
MGRX
Mangoceuticals, Inc.
1.20+0.06
MRMD
MariMed Inc.
0.12+0.01
OVATF
OVATION SCIENCE INC
0.03+0.00
TDOC
Teladoc Health, Inc.
7.41+0.07
ZTS
Zoetis Inc.
123.23+2.25